Latest Breaking News On - Idorsia japan - Page 1 : comparemela.com

Daridorexant for Insomnia Nears Approval in Japan

A new drug application has been submitted in Japan for the approval of daridorexant, a dual orexin receptor antagonist for insomnia.

Sosei heptaresMakoto uchiyamaNihon universityMochida pharmaceutical co ltdIdorsia pharmaceuticals ltdIdorsia pharmaceuticals japan ltdSosei groupIdorsia pharmaceuticals korea co ltdToho universityJapanese pharmaceuticalsDevices agencyMedical devices agencyIdorsia japanTokyo adachi hospital

Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 20, 2023 Idorsia Ltd today announced the sale of its operating businesses in the Asia Pacific region , including.

Switzerland generalUnited kingdomCity ofRepublic ofSouth koreaNew zealandAndrewc weissSosei heptaresNeurocrine biosciencesGenentech rocheSatoshi tanakaChris cargillJean paul clozelAsia pacificSosei group corporationSwiss exchange

newratings de

newratings de
newratings.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newratings.de Daily Mail and Mail on Sunday newspapers.

New zealandCity ofUnited kingdomSwitzerland generalRepublic ofSouth koreaSosei heptaresNeurocrine biosciencesGenentech rocheAsia pacificChris cargillJean paul clozelSatoshi tanakaAndrewc weissIhre freundeHead of investor relations corporate communications

GNW-Adhoc: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - July 20, 2023 Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region ("Territory"), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in .

Switzerland generalUnited kingdomRepublic ofNew zealandSouth koreaCity ofSatoshi tanakaAsia pacificSosei heptaresAndrewc weissJean paul clozelChris cargillGenentech rocheNeurocrine biosciencesHead of investor relations corporate communicationsGroup corporation

Idorsia Pharmaceuticals Ltd: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million

Idorsia Pharmaceuticals Ltd: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandRepublic ofSouth koreaSwitzerland generalCity ofNeurocrine biosciencesAndrewc weissSosei heptaresJean paul clozelAsia pacificGenentech rocheSatoshi tanakaChris cargillTokyo stock exchangeSwiss exchange